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The diagnosis of acute kidney injury (AKI) is usually based on
changes in serum creatinine, but such measurements are a
poor marker of acute deterioration in kidney function. We
performed a systematic review of publications that evaluated
the accuracy and reliability of serum and urinary biomarkers
in human subjects when used for the diagnosis of
established AKI or early AKI, or to risk stratify patients with
AKI. Two reviewers independently searched the MEDLINE and
EMBASE databases (January 2000–March 2007) for studies
pertaining to biomarkers for AKI. Studies were assessed for
methodologic quality. In total, 31 studies evaluated 21
unique serum and urine biomarkers. Twenty-five of the 31
studies were scored as having ‘good’ quality. The results of
the studies indicated that serum cystatin C, urine interleukin-
18 (IL-18), and urine kidney injury molecule-1 (KIM-1)
performed best for the differential diagnosis of established
AKI. Serum cystatin C and urine neutrophil gelatinase-
associated lipocalin, IL-18, glutathione-S-transferase-p, and
c-glutathione-S-transferase performed best for early
diagnosis of AKI. Urine N-acetyl-b-D-glucosaminidase, KIM-1,
and IL-18 performed the best for mortality risk prediction
after AKI. In conclusion, published data from studies of serum
and urinary biomarkers suggest that biomarkers may have
great potential to advance the fields of nephrology and
critical care. These biomarkers need validation in larger
studies, and the generalizability of biomarkers to different
types of AKI as well as the incremental prognostic value over
traditional clinical variables needs to be determined.
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The diagnosis of acute kidney injury (AKI—formally known as
acute renal failure) is usually based on either an elevation of
serum creatinine or the detection of oliguria.1 Serum creatinine
is a poor marker of early renal dysfunction, because serum
concentration is greatly influenced by numerous non-renal
factors (such as body weight, race, age, gender, total body
volume, drugs, muscle metabolism, and protein intake).2 The
utility of serum creatinine is worse in AKI, because the patients
are not in steady state; hence, serum creatinine lags far behind
renal injury. Thus, substantial rises in serum creatinine are often
not witnessed until 48–72 h after the initial insult to the
kidney.1,3 In addition, significant renal disease can exist with
minimal or no change in creatinine because of renal reserve,
enhanced tubular secretion of creatinine, or other factors.4,5
A ‘troponin-like’ biomarker of AKI that is easily measured,
unaffected by other biological variables, and capable of both
early detection and risk stratification would substantially assist
the diagnosis of AKI.
The American Society of Nephrology has designated the
development of biomarkers for early detection of AKI as a
top research priority.6 Several biomarkers of AKI have been
identified over the past few years that are elevated in ischemic
renal injury in experimental animals, and also in humans
with clinical AKI, in some cases prior to a ‘gold standard’
diagnostic threshold (for example, rise in serum creatinine by
50%).7,8 These biomarkers include both serum tests such as
cystatin C,9 and urinary tests such as interleukin-18 (IL-18)10
and neutrophil gelatinase-associated lipocalin (NGAL),11
along with several others. Uncertainty still exists, however,
as to whether these biomarkers possess adequate prognostic
accuracy for both established AKI and for early detection of
AKI. Limited data are available that directly compare the
performance of these biomarkers as tests for diagnosis of
AKI, and their consistency across certain subgroups of
patients (for example, post-cardiac surgery, sepsis, post-
kidney transplant). Finally, the differences in the reporting
criteria for ‘positivity’ have made it difficult to compare the
performance of these various biomarkers directly.
Our objectives were to evaluate, in human subjects, the
accuracy and reliability of serum and/or urinary biomarkers
for the diagnosis of established AKI, for the early diagnosis of
AKI, and for risk stratification of AKI.
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RESULTS
The combined search identified a total of 830 citations, of
which 715 were judged ineligible after title and abstract
review (Figure 1). The major reasons for exclusion were study
populations without AKI or acute renal failure, non-serum or
non-urine biomarker of diagnosis of AKI, and duplicate
publications. Full text analysis of the remaining 115 articles
led to 31 studies9–36 meeting inclusion criteria (Tables 2–4).
The methodological quality based on scoring of the 10
validity criteria taken from the STARD (Standards for
Reporting of Diagnostic Accuracy) recommendations is listed
in Table 1. Only tests with results that were scored of good or
fair quality are described in the text below.
Biomarker performance
Diagnosis of established AKI. Serum biomarkers. Cystatin
C, a marker of glomerular filtration, performed extremely
well for identifying established AKI (receiver operating curve
(area under the curve (AUC)) 0.88–0.97)13,15–17 (Table 2).
Serum NGAL, a marker of renal tubular inflammation rather
than glomerular filtration, correlated well with acute changes
in serum creatinine in two studies.19,26 Finally, carbamylated
hemoglobin performed quite well in differentiating AKI from
elevated creatinine due to chronic kidney disease (CKD).18
Urine biomarkers. Urine IL-18 (a marker of renal tubular
inflammation) concentrations were significantly greater in
patients with acute tubular necrosis vs all other types of
patients (healthy controls, prerenal azotemia, UTI, and
CKD).20 The AUC of IL-18 for the diagnosis of established
AKI (acute tubular necrosis) was nearly flawless (0.95) in this
cohort.
Kidney injury molecule-1 (KIM-1) is renal tubular protein
that has been demonstrated to be elevated in experimental
animals with AKI. Clinical studies reveal that KIM-1 is highly
effective at distinguishing true acute tubular necrosis from
other types of renal injury (including CKD) or controls.22,37
In the first published report, a 1 U increase in KIM-1 was
associated with 12-fold higher odds for ischemic acute
tubular necrosis.40 In the second report, the AUC of KIM-1
for the diagnosis of AKI was 0.90.37 Two other biomarkers
(enzymes that are normally filtered and degraded) were also
tested in this cohort. N-acetyl-b-D-glucosaminidase (NAG)
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Figure 1 | Selection of Studies. RRT, renal replacement therapy.
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Table 1 | Scoring system for validity used in this systematic review
Validity Criterion Explanation Scoring Comments
Participant
recruitment
Was recruitment based on presenting
symptoms, results from previous tests, or fact
that participants received index tests?
Presenting sx=1
Previous tests or
index tests=0
Based on presenting symptoms in all 31
studies.
Participant
sampling
Was it study population or a convenience
sample or a consecutive series?
Consecutive
series=1
Convenience
sample=0
Based on convenience sample in
510,19,20,22,25,37 studies.
Data collection Was data collection planned before the index
test and reference standard were performed
prospectively or retrospectively?
Prospective=1
Retrospective=0
Planned and performed prospectively in all 31
studies.
Reference
standard
Was the rationale for the reference standard
stated?
Stated=1
Not stated=0
Not stated for two12,18 studies.
Materials and
methods
Were technical specifications of material and
methods stated including how and when
measurements were taken?
Stated=1
Not stated=0
Stated in all but one19 of the articles.
Index test Were the definitions of and rationales for the
units, cutoffs, and/or categories of the results
of the index tests stated?
Stated=1
Not stated=0
Not stated in two12,19 of the 31 articles.
Blinding Were readers of index test and reference
standard blinded?
Blinded=1
Not blinded or
not stated=0
Stated that the readers of index test and
reference standard were blinded in
1710,11,19,29,30,35–39 articles.
Completion Was the number of participants that did not
undergo index tests (no. of tests vs sample
size) stated?
Stated=1
Not stated=0
Stated in all but one19 of the studies.
Time interval Was the time interval from index test to
reference standard stated?
Stated=1
Not stated=0
The time interval between index test and
reference standard (clinical diagnosis of AKI or
severity end point such as dialysis or death)
was not stated in five19,20,25,34,36 articles.
Distribution of
severity of
disease
Was there a representative distribution of
severity of disease? (mild, moderate, severe
AKI; non-oliguric vs oliguric)
Yes=1
No=0
A broad distribution of disease severity was
found in all but four 12,25,27,37 of the studies.
Table 2 | Studies of biomarkers for diagnosis of established AKI
References Biomarker Clinical setting Subjects
Sensitivity/
specificity
Area under
ROC LR
Quality
score
Serum
Abu-Omar et al.12 Cystatin C Cardiac surgery 60 NR NR N/A 6
Biancofiore et al.13 Cystatin C Post-OLT 68 0.967/0.85 NR 6.4 9
Benohr et al.14 Cystatin C Cisplatin Rx 41 NR NR N/A 9
Stabuc et al.15 Cystatin C Cisplatin Rx 72 0.87/1.0 0.967 Infinity 9
Zhu et al.16 Cystatin C Cardiac surgery 60 NR 0.876 N/A 9
Villa et al.17 Cystatin C ICU 50 NR 0.927 N/A 9
Wynckel et al.18 Carbamylated
Hb
Hospitalized 41 0.94/0.92 NR 11.8 8
Mori et al.19 NGAL Hospitalized 37 NR NR N/A 5
Bachorzewska-
Gajewska et al.26
NGAL PCI 35 NR NR NR 9
Urine
Mori et al.19 NGAL Hospitalized 46 NR NR N/A 5
Bachorzewska-
Gajewska et al.26
NGAL PCI 35 NR NR N/A 9
Parikh et al.20 IL-18 Hospitalized 72 0.85/0.88 0.95 7.1 7
Boldt et al.21 GST, NAG,
a-1-M
Cardiac surgery 80 NR NR N/A 9
Han et al.22 KIM-1 Hospitalized 32 NR NR 12.4w 8
Han et al.37 KIM-1 Hospitalized 74 NR 0.90 N/A 8
Han et al.37 MMP-9 Hospitalized 74 NR 0.74 N/A 8
Han et al.37 NAG Hospitalized 74 NR 0.97 N/A 8
du Cheyron et al.23 NHE3 ICU 68 NR NR N/A 9
a-1-M, alpha-1 microglobulin; AKI, acute kidney injury; AP, alkaline phosphatase; CKD, chronic kidney disease; ESRD, end stage renal disease; GFR, glomerular filtration rate;
GGT, g-glutamyltransferase; GST, glutathione-S-transferase; GT, glutamyl transpeptidase; ICU, intensive care unit; KIM-1, kidney injury molecule-1; LDH, lactate dehydrogenase;
LR, likelihood ratio; MMP-9, matrix metalloproteinase-9; N/A, not applicable; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NHE3,
sodium hydrogen exchanger 1; NR, not reported; OLT, orthotopic liver transplantation; PCI, percutaneous coronary intervention; ProANP, prohormone of atrial natriuretic
peptide; Rx, treatment; RIFLE, Risk Injury Failure Loss End-stage Renal Disease; ROC, receiver operating curve.
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was excellent at identifying cases of AKI (AUC 0.97), yet
matrix metalloproteinase-9 (MMP-9) did not fare as well to
identify AKI (AUC 0.74).37 In the same study, the combina-
tion of KIM-1, NAG, and MMP-9 yielded perfect results
(AUC 1.0) for diagnosing AKI.
Sodium–hydrogen exchanger isoform-3 (NHE-3) is an
abundant proximal tubular protein that is shed into the urine
after tubular injury. One clinical study23 demonstrated that
urinary NHE-3 was elevated by sixfold in patients with AKI
compared to controls with prerenal azotemia.
Early diagnosis of AKI. Serum biomarkers. The two
studies9,24 of cystatin C that were of good methodologic
quality demonstrated excellent accuracy for the early
diagnosis of AKI at 24 and 48 h before the clinical diagnosis
of AKI,9 or in another study performed on days 1–3 of
admission to the medical intensive care unit (Table 3).24
Serum NGAL was significantly higher in children with AKI
following cardiac surgery compared to controls, and
possessed excellent specificity, but its sensitivity for the early
diagnosis of AKI was low (Table 3).11 In a study of 75 adult
patients undergoing cardiac surgery, peri-operative elevations
of CD11b (an inflammatory marker) had high odds for the
development of AKI (Table 3).27 The peak CD11b increase
also correlated with the percentage change in creatinine.
Urine biomarkers. The two biomarkers studied most often
for early diagnosis of AKI have been urine NGAL and IL-18.
In a study of children undergoing cardiac surgery,11 the
urinary concentration of NGAL 2 h post-surgery possessed
nearly 100% accuracy for correctly identifying AKI 24–72 h
after surgery (Tables 3 and 5). In contrast, subsequent studies
have not yielded results as robust as those witnessed in the
initial study. In a cohort of adults undergoing cardiac
surgery,28 the best AUC for urinary NGAL concentration was
only 0.80 at a time point of 18 h after surgery. Other time
points, both immediately after surgery (2 and 12 h) and 24 h
after surgery, did not possess diagnostic accuracy as high
(Table 5). Similar, less robust results were demonstrated in a
cohort of critically ill children,38 in which urine NGAL 48 h
prior to a clinical diagnosis of AKI was only moderately
accurate at predicting AKI (Table 3). In a different
population (post-kidney transplant), urine NGAL was
quite successful at predicting the outcome of AKI
(dialysis-requiring delayed graft function).29 Thus, NGAL
performed extremely well in two specific populations
Table 3 | Studies of biomarkers for the early diagnosis of AKI
References Biomarker Clinical setting Subjects
Sensitivity/
specificity
Area under
ROC
Positive
LR
Quality
score
Serum
Herget-Rosenthal
et al.9
Cystatin C ICU 85 0.82/0.95 NR 16.4 9
Ahlstrom et al.24 Cystatin C ICU 202 NR 0.901 N/A 9
Mazul-Sunko et al.25 Cystatin C ICU 29 0.5/0.5 NR 1.0 6
Mazul-Sunko et al.25 ProANP(1-98) ICU 29 NR/NR NR N/A 6
Mishra et al.11 NGAL Cardiac surgery in
children
71 0.70/0.94 NR 11.6 10
Rinder et al.27 Neutrophil
CD11b
Cardiac surgery 75 NR NR 62.6w 8
Urine
Mishra et al.11 NGAL Cardiac surgery in
children
71 1.0/0.98 0.998 50.0 10
Wagener et al.28 NGAL Cardiac surgery 81 0.73/0.78 0.8 3.3 9
Zappitelli et al.38 NGAL Critically ill
children
140 0.77/0.72 0.78 2.75 10
Parikh et al.29 NGAL Post-transplant 63 0.9/0.83 0.9 5.3 10
Parikh et al.10 IL-18 ICU 138 0.5/0.85 0.73 3.3 9
Parikh et al.29 IL-18 Post-transplant 63 NR 0.9 N/A 10
Parikh et al.30 IL-18 Cardiac surgery 71 0.5/0.94 0.75 8.3 10
Han et al.40 IL-18 Critically ill
children
137 0.25/0.81 0.54 1.3 10
Han et al.37 KIM-1 Cardiac surgery 40 0.74/0.90 0.83 3.16 8
Han et al.37 NAG Cardiac surgery 40 1.0/0.3 0.69 1.43 8
Han et al.37 MMP-9 Cardiac surgery 40 NR 0.50 N/A 8
Eijkenboom et al.31 GST Cardiac surgery 84 NR NR N/A 9
Westhuyzen et al.32 g-GT ICU 26 1.0/0.9 0.95 10.0 9
Westhuyzen et al.32 p-GST ICU 26 1.0/0.9 0.929 10.0 9
Westhuyzen et al.32 a-GST ICU 26 0.75/0.9 0.893 7.5 9
Westhuyzen et al.32 AP ICU 26 0.5/0.95 0.863 10.0 9
Westhuyzen et al.32 NAG ICU 26 1.0/0.81 0.845 5.3 9
Westhuyzen et al.32 LDH ICU 26 0.5/0.95 0.688 10.0 9
AKI, acute kidney injury; AP, alkaline phosphatase; GST, glutathione-S-transferase; GT, glutamyl transpeptidase; ICU, intensive care unit; IL, interleukin; KIM-1, kidney injury
molecule-1; LDH, lactate dehydrogenase; LR, likelihood ratio; MMP-9, matrix metalloproteinase-9; N/A, not applicable; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil
gelatinase-associated lipocalin; NR, not reported; ProANP, prohormone of atrial natriuretic peptide; ROC, receiver operating curve.
wOdds ratio rather than true LR.
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(children undergoing cardiac surgery and patients receiving
kidney transplantation), but did not perform as well in adults
undergoing cardiac surgery or in critically ill children.
Four studies10,29,30,39 of urinary IL-18 as an early
predictive biomarker of AKI are included in this review.
The AUCs for IL-18 in these four studies varied markedly
(0.54–0.9) for the early diagnosis of AKI. In general, IL-18
demonstrated low sensitivity but high specificity (Table 3). As
noted for NGAL, the performance of IL-18 also is dependent
on the timing of collection in relation to the exposure (for
example, the stressor such as cardiac surgery) and the
outcome (development of AKI).10,30 Of note, IL-18 concen-
tration remained an independent predictor for AKI even after
adjustment for several clinical variables.10,39 In summary,
elevations in urine IL-18 concentration are rarely false
positive elevations, however, many patients with AKI do
not have elevations in urine IL-18.
The ability of KIM-1 to predict clinical AKI early has only
been evaluated in one published study to date. It appears that
KIM-1 is not as accurate in early prediction of AKI, but is
better at identifying established AKI (Table 5).37
Prognosis of AKI (severity of AKI). Several of the same
biomarkers mentioned above were evaluated not only for
diagnosis of AKI but also for risk stratification and prognosis
of AKI.
Serum biomarkers. In one study, on the same day that
the criterion for meeting the RIFLE-R definition of AKI
(rise in serum creatinine X50%) was observed, the positive
predictive value of elevations in serum cystatin C for the need
for renal replacement therapy (RRT) was 78% and the AUC
was 0.76 (Table 4).9 Serum NGAL levels were unable to
discriminate between children who did not require RRT and
those who subsequently required RRT, regardless of various
cutoff values examined.33
Urine biomarkers. Urinary NGAL within the first 5 days of
hospitalization possessed high sensitivity but low specificity
for the subsequent need for dialysis in a study of pediatric
hemolytic uremic syndrome.33 Another study30 demons-
trated that urine NGAL at 4 h after cardiac surgery correlated,
albeit weakly, with the number of days of AKI (r2¼ 0.22;
P¼ 0.005). In a different study, however, urine NGAL
concentration was minimally useful for predicting persistent
AKI (AUC 0.63) or for worsening AKI (AUC 0.61).38 Thus,
the utility of NGAL to predict severity of AKI is certainly
mixed.
Similar types of weakly positive results for the ability
of urine IL-18 to predict severity of AKI have been demons-
trated. Urine IL-18 at 4 h after cardiac surgery weakly
correlated with number of days with AKI (r2¼ 0.18;
P¼ 0.01).30 In another study, the ability for IL-18 to predict
severe AKI (duration 448 h) varied depending on the cutoff
used.39
While the inflammatory biomarkers (NGAL, IL-18) did
not fare extremely well in predicting severe AKI, it appears
that tubular proteins and enzymes may be of greater yield for
risk-stratification. In 73 patients with non-oliguric AKI, four
Table 4 | Studies of biomarkers for predictors of severity of AKI
References Biomarker
Clinical
setting
Definition of
severe AKI
Sensitivity/
specificity
Area under
ROC LR
Quality
score
Serum
Herget-Rosenthal et al.9 Cystatin C ICU RRT 0.82/0.93 0.76 11.7 9
Ahlstrom et al.24 Cystatin C ICU Death NR 0.624 N/A 9
Trachtman et al.33 NGAL HUS RRT NR NR NR 9
Simmons et al.34 IL-6 ICU Death NR NR 1.65w 9
Simmons et al.34 IL-8 ICU Death NR NR 1.54w 9
Simmons et al.34 IL-10 ICU Death NR NR 1.34w 9
Urine
Parikh et al.10 IL-18 ICU Death NR NR 1.6w 9
Han et al.40 IL1-8 Critically ill
children
Duration448 h 0.53/0.71 NR 1.8 10
Trachtman et al.33 NGAL HUS RRT 0.9/0.54 NR 2.0 9
Zappitelli et al.38 NGAL Critically ill
children
Duration448 h NR 0.63 NR 10
Herget-Rosenthal et al.35 Cystatin C ICU RRT 0.92/0.83 0.92 5.4 10
Herget-Rosenthal et al.35 a-Microglobulin ICU RRT 0.88/0.81 0.86 4.6 10
Herget-Rosenthal et al.35 Retinol-binding
protein
ICU RRT NR 0.8 N/A 10
Herget-Rosenthal et al.35 b-2 microglobulin ICU RRT NR 0.51 N/A 10
Herget-Rosenthal et al.35 NAG ICU RRT 0.85/0.62 0.81 2.2 10
Herget-Rosenthal et al.35 a-GST ICU RRT NR 0.64 N/A 10
Herget-Rosenthal et al.35 GGT ICU RRT NR 0.64 N/A 10
Herget-Rosenthal et al.35 LDH ICU RRT NR 0.59 N/A 10
Han et al.37 NAG Hospitalized RRT or death NR 0.71 3w 9
Han et al.37 KIM-1 Hospitalized RRT or death NR 0.61 1.4w 9
AKI, acute kidney injury; GGT, g-glutamyltransferase; GST, glutathione-S-transferase; GT, glutamyl transpeptidase; HUS, hemolytic uremic syndrome; ICU, intensive care unit;
IL, interleukin; KIM-1, kidney injury molecule-1; LDH, lactate dehydrogenase; LR, likelihood ratio; MMP-9, matrix metalloproteinase-9; N/A, not applicable; NAG, N-acetyl-b-D-
glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NR, not reported; ROC, receiver operating curve; RRT, renal replacement therapy.
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urine biomarkers performed well for predicting RRT.35 The
four biomarkers were urinary cystatin C, a-1 microglobulin,
NAG, and retinol-binding protein (AUCs 0.92, 0.86, 0.80,
and 0.81, respectively). Four other biomarkers that were
assessed did not perform as well (Table 4). In a different
study of 201 hospitalized patients, NAG again proved to be of
prognostic value, as a dose-dependent association for the
prediction of the composite end point of dialysis or death was
demonstrated.36 In fact, patients with NAG concentrations in
the upper quartile possessed ninefold higher odds for
development of the composite end point compared to those
in the lowest quartile, and this relationship remained
significant after adjustment for co-variates. In this same
study,36 the association between the KIM-1 concentration
and the composite end point (dialysis or death) was weaker
(odds ratio 3.2 for highest vs lowest quartile) and was no
longer significant after adjustment for co-variates.
Prognosis of AKI (AKI-associated death). Risk stratification
of AKI can also be defined in terms of death, as opposed to
the need for dialysis or duration of AKI. Some studies have
tried to predict death in the setting of AKI via biomarkers.
Serum biomarkers. The results of serum cystatin C for
predicting AKI-associated death were modest (Table 4).24
The cytokines IL-6, IL-8, and IL-10 were significantly higher
in non-survivors vs survivors in a cohort of adults with AKI,
but after adjustment for co-variates, the statistically signi-
ficant relationship was lost (Table 4).34
Urine biomarkers. Urine NGAL was not associated with
mortality in the only study that examined this relationship.38
IL-18 has been shown to predict mortality in adult10 and
pediatric critically ill populations.39
Finally, as mentioned above, the association and perfor-
mance characteristics of NAG activity and KIM-1 level jointly
and the composite outcome of dialysis and death were
Table 5 | Relationship between timing of biomarker collection and test characteristics (when reported)
References Biomarker
Cutoff for
biomarker
AKI definition
(change in
creatinine) Setting Timing
Sensitivity/
specificity
Area
under
ROC LR
Early diagnosis of AKI
Serum
Herget-Rosenthal et al.9 Cystatin C 450% rise 450% rise ICU 2 days prior to clinical AKI 0.55/0.95 0.82 11.0
1 day prior to clinical AKI 0.82/0.95 0.97 16.4
4100% rise 4100% rise ICU 2 days prior to clinical AKI 0.39/1.0 0.92 Infinity
1 day prior to clinical AKI 0.76/1 0.98 Infinity
4200% rise 4200% rise ICU 2 days prior to clinical AKI 0.4/1 0.97 Infinity
1 day prior to clinical AKI 0.85/1 0.99 Infinity
Ahlstrom et al.24 Cystatin C NR 4300% rise ICU Day 1 after admission to ICU NR 0.885 N/A
Day 2 after admission to ICU NR 0.893 N/A
Day 3 after admission to ICU NR 0.901 N/A
Urine
Mishra et al.11 NGAL 50 mg l1 450% rise Cardiac surgery 2 h post-surgery 1.0/0.98 0.998 50.0
4 h post-surgery 0.95/1.0 1 Infinity
Wagener et al.28 NGAL 213 ng ml1 450% rise Cardiac surgery 1 h post-surgery 0.8/0.59 0.68 2.0
3 h post-surgery 0.69/0.65 0.737 2.0
18 h post-surgery 0.73/0.78 0.8 3.3
24 h post-surgery 0.8/0.73 0.68 3.0
Parikh et al.30 IL-18 50 pg ml1 450% rise Cardiac surgery 4 h post-surgery 0.25/0.97 0.61 8.3
12 h post-surgery 0.5/0.94 0.75 8.3
24 h post-surgery 0.4/0.94 0.73 6.7
Parikh et al.10 IL-18 100 pg ml1 450% rise ICU 2 days prior to clinical AKI NR 0.65 N/A
1 day prior 0.5/0.85 0.73 3.3
Han et al.37 KIM-1 — Cardiac surgery 2 h post-surgery NR 0.57 N/A
7 ng mg1 creat 450% rise 6 h post-surgery 0.85/0.21 0.52 1.1
7 ng mg1 creat 450% rise 12 h post-surgery 0.32/0.90 0.83 3.2
7 ng mg1 creat 450% rise 24 h post-surgery 0.35/0.90 0.78 3.5
— 36 h post-surgery NR 0.84 N/A
— 48 h post-surgery NR 0.81 N/A
Han et al.37 NAG — Cardiac surgery 2 h post-surgery NR 0.65 N/A
25 U mg1 Ucr 450% rise 6 h post-surgery NR 0.58 1.4
25 U mg1 Ucr 450% rise 12 h post-surgery 1.0/0.3 0.69 1.4
25 U mg1 Ucr 450% rise 24 h post-surgery 0.85/0.25 0.70 1.1
— — 36 h post-surgery NR 0.71 N/A
— — 48 h post-surgery NR 0.66 N/A
Predictors of Severity of AKI
Herget-Rosenthal et al.9 Cystatin C 450% rise RRT ICU 2 days prior to clinical AKI 0.53/0.82 0.69 2.9
1 day prior to clinical AKI 0.76/0.93 0.75 10.9
Day of diagnosis of clinical AKI 0.82/0.93 0.76 11.7
Ahlstrom et al.24 Cystatin C NR Death ICU Day 1 after admission to ICU NR 0.624 N/A
Day 2 after admission to ICU NR 0.598 N/A
Day 3 after admission to ICU NR 0.581 N.A
AKI, acute kidney injury; ICU, intensive care unit; IL, interleukin; KIM-1, kidney injury molecule-1; LR, likelihood ratio; N/A, not applicable; NAG, N-acetyl-b-D-glucosaminidase;
NGAL, neutrophil gelatinase-associated lipocalin; NR, not reported; ROC, receiver operating curve.
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examined in one study and added a modest amount of
prognostic value to traditional clinical severity of illness
variables.36
DISCUSSION
This systematic review is a novel evaluation of biomarkers for
the diagnosis of AKI as reported in the literature. Before a
new biomarker can be deemed clinically useful, it requires
validation in multiple cohorts, it must be reliable, and it must
provide incremental prognostic information over traditional
markers and models. This systematic review finds that
although some serum and urine biomarkers perform well
for the early diagnosis of AKI, the diagnosis of established
AKI, or risk stratification of AKI, methodological short-
comings exist in some of the studies, and the reliability and
reproducibility of the findings have not yet been demons-
trated.
The generalizability of the data to broad patient popula-
tions is also not yet manifest, as the test performance varied
among different patient types (children vs adult; cardiac
surgery vs transplant vs critically ill). Many studies excluded
patients with pre-existing renal failure (CKD). In fact, 22 of
the 31 studies excluded patients if they possessed underlying
CKD. This approach again limits generalizability, because
approximately 30% of patients admitted to intensive care
units have pre-existing CKD,41 and patients with CKD are at
higher risk for development of AKI than those with normal
baseline renal function.42,43
In addition, several studies did not provide sensitivity,
specificity, positive predictive value (PPV), negative pre-
dictive value (NPV), and area under receiver operator curves
of the biomarkers for the diagnosis or risk stratification of
AKI. Many studies reported odds ratio or relative risk (RR).
Reporting of odds ratio or relative risk is typical in
epidemiologic studies to demonstrate the strength of
association between risk factor and the disease. Use of these
measures, however, is not adequate to determine the
performance of a biomarker for classifying disease or
predicting risks in people. Strong statistical associations
(odds ratio or relative risk) between a biomarker and an
outcome do not necessarily imply that the biomarker can
discriminate between persons likely to have the outcome and
those who do not.44 Instead, the accuracy or validity of a
marker for classifying persons is better summarized by
reporting its true-positive fraction (or sensitivity) and its
false-positive fraction (also known as 1specificity). A
perfect marker will have true-positive fraction¼ 1 and
false-positive fraction¼ 0, but the criteria by which the
marker is judged useful will depend entirely on the context in
which it is to be used. For example, if one is using a
biomarker to determine who will need an invasive procedure
or risky treatment, then an extremely low false-positive
fraction (o2%) is needed to avoid placing patients at risk for
these procedures or treatments. Thus, characterization of
false-positive and false-negative errors is not equivalent and
must be reported separately.
Our review found that some studies of biomarkers were
biased in various ways. The most common bias we
encountered was ‘review bias,’ as the examiner and the
person who evaluated the experimental and reference test
results were not stated to be blinded in 14 of the 31 studies.
Second, ‘selection bias’ was present in nearly 20% of studies,
as members of the cohort were enrolled non-consecutively.
Third, ‘workup detection bias’ was a concern overtly in five
studies, because the time interval between the experimental
test (biomarker) and the disease (clinical AKI) was not stated.
Although some studies measured biomarker concentrations
at multiple intervals following the stressor (for example,
cardiac surgery, intensive care unit admission), the interac-
tion between these times and the degree of accuracy was not
thoroughly explored and discussed in several studies. The
importance of this issue is critical, as in clinical practice, it is
unrealistic for a test to be utilized only at one precise point in
time (for example, 24 h before a clinical diagnosis of AKI,10
or 18 h after cardiac surgery28). Thus, when the results of all
of the biomarker studies are scrutinized closely, certain
patterns of biomarker elevation are evident (Table 5). In
general, the biomarkers were most accurate when measured
closer to the clinical diagnosis of AKI.
Aside from the limitations of the available studies on
serum and urinary biomarkers, there are positive aspects that
can be extended in future studies of biomarkers for AKI.
Urine IL-18, KIM-1, and NAG performed extremely well in
some studies evaluating the diagnosis of established AKI.
Serum cystatin C and urine NGAL, IL-18, glutathione-
S-transferase-p, and g-glutathione-S-transferase performed
best for facilitating early diagnosis of AKI and NAG. KIM-1
and IL-18 performed best for mortality risk prediction after
AKI. These biomarkers can be considered candidates for
phases 3 and 4 clinical biomarker studies.
It is unclear if biomarkers of AKI will have incremental
benefit over traditional markers or variables before their
adoption in the scientific and clinical community. Only a few
studies (n ¼ 910,25,29,30,32,34,36,38,39) in this systematic review
compared the individual biomarkers to traditional clinical
variables or to clinical models that have been used for
prediction of AKI, or its severity and outcome; and only six
studies assessed the independent association of biomarkers
with outcomes via multivariate analyses.10,27,29,30,34,39 It
should be noted, however, that the two most widely used
biomarkers in clinical practice (serum troponin for acute
myocardial infarction and brain natriuretic peptide for
congestive heart failure) are used largely in isolation of other
clinical variables.
Biomarkers that have performed well to date will need to
be validated in a broad spectrum of patient populations
(cardiac surgery, critically ill, post-transplant, underlying
CKD). In addition, the patterns of the timing of collection of
the biomarker in relationship to the clinical outcome will
need to be delineated more clearly. Finally, the combination
of biomarker panels (such as the panel for acute MI
composed of CK, CK-MB, and troponin) will likely need
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creation and validation. We anticipate that a battery of
biomarkers will need to be implemented to accurately
identify patients with established AKI (for example, serum
cystatin C, urine IL-18, and urine KIM-1), diagnose AKI
early (for example, serum cystatin C, and urine NGAL), and
risk-stratify patients for the need for dialysis or death (for
example, urine KIM-1, NAG, and IL-18). If these panels are
validated and show robust results, an opportunity may exist
to conduct clinical trials of therapeutics for the treatment of
AKI and thus improve outcomes of AKI in the near future.
MATERIALS AND METHODS
Studies eligible for review
Studies were eligible if they were prospective or retrospective cohort
studies, case–control studies, or randomized controlled trials
evaluating the use of serum or urinary biomarkers for the diagnosis
or risk stratification of AKI. Studies must have contained 20 or more
human subjects.
Finding relevant studies
We searched the MEDLINE and EMBASE databases (2000–May
2007), utilizing the search terms ‘acute renal failure’ or ‘acute kidney
injury’ or ‘creatinine blood level’ in conjunction with ‘biomarker’ or
‘biologic marker,’ with the following limits: humans, 2000–2007,
diagnosis (sensitivity), adults. Trials that attempted to ascertain the
diagnostic value of any serum or urinary biomarker were reviewed.
We identified potentially relevant studies using a manual search of
references from all eligible studies, review articles, Science Citation
Index Expanded on the Web of Science, and through searching the
top 50 citations for each paper through the ‘related articles’ feature
of PubMed. The search was restricted to the English language.
Quality assessment
Two reviewers (SGC and RY) independently searched trials for
inclusion and assessed methodological quality; the two reviewers
selected all studies suitable for review. Disagreements were discussed
until the decision to include or exclude an individual study was
unanimous. Studies were assessed for validity using a modified
checklist of the STARD criteria.45 Studies were scored as ‘good’
quality if the score was X9, ‘fair’ quality if the score was 7–8, and
‘poor’ quality if the score wasp6. The STARD initiative developed a
set of 25 criteria for reporting of studies of diagnostic accuracy
during a consensus meeting on September 16 and 17, 2000.45 The
original STARD checklist contained 25 items. For the purposes of
our review, however, we limited our quality assessment to 10 out of
the 25 criteria that addressed issues of validity (Table 1).
Data abstraction
Data were extracted using prepared data extraction forms. Review
Manager software (Revman 2003; Version 4.2) was used for
statistical analyses. Studies were separated into three groups: those
evaluating biomarkers for the diagnosis of established AKI, those
evaluating biomarkers for the early diagnosis of AKI, and those
evaluating biomarkers for the prognosis or severity of AKI.
Sensitivity and specificity were abstracted from the trials and
converted into likelihood ratios, such that the likelihood ratios were
equal to sensitivity/(1specificity). The receiver operator curve, as
the prime statistic for evaluation of the accuracy of continuous
biomarkers for outcomes, was abstracted, because it describes a
whole set of potential result combinations (for example, true-
positives, false-positives) for different cutoff values, does not depend
on how the marker is coded, and provides a natural common scale
for comparing different markers even when they are measured in
completely different units. An AUC value of 0.5 is equivalent to a
‘coin flip,’ and a value of 1.0 indicates a perfect test.
Our research protocol included a plan to pool likelihood ratios as
relative risks (and 95% confidence intervals), and to use sensitivity
analyses to evaluate the effect of the trial quality and underlying
patient type (critically ill, post-cardiac surgery, post-renal trans-
plant, and so on). Pooling of results was not undertaken, however,
due to marked heterogeneity in cutoffs for definitions in both the
new index test and the reference ‘gold standard’ definition of AKI
among studies of similar biomarkers.
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